{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:17:56Z","timestamp":1788175076728,"version":"build-2803163510"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study evaluated the efficacy, safety, and drug retention of anakinra and canakinumab in paediatric patients with colchicine-resistant familial Mediterranean fever (cr-FMF) within a real-world cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study was conducted from June 2016 to April 2024, including 86 patients diagnosed with cr-FMF. Clinical and laboratory parameters, including attack frequency, C-reactive protein, serum amyloid A, and autoinflammatory disease activity index (AIDAI) scores, were recorded at baseline and during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 86 patients (50 females, 36 males) were included in the study. All carried exon 10 MEFV mutations, with 69 patients (80.2%) having the M694V\/M694V genotype. Anakinra was initiated in 36 patients (41.9%), and canakinumab in 50 patients (58.1%). The median treatment duration was significantly longer for canakinumab (48\u00a0months) compared to anakinra (7\u00a0months) (P\u2009&amp;lt;\u2009.001). Both treatments significantly reduced attack frequency, AIDAI scores, C-reactive protein, and serum amyloid A levels compared to baseline (P\u2009&amp;lt;\u2009.001). While the reduction in attack frequency was comparable between the groups, patients treated with canakinumab achieved significantly lower mean AIDAI scores at 12\u00a0months compared to the anakinra group (P\u2009=\u2009.021). Anakinra provided a more rapid onset of symptom control but was commonly discontinued due to injection site reactions (44.4%). Canakinumab was associated with sustained long-term disease control with fewer local side effects. However, rare serious events, including acute myeloid leukaemia and inflammatory bowel disease, were observed, though causality with treatment could not be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this paediatric cohort of cr-FMF patients, both anakinra and canakinumab were effective in reducing disease activity and inflammation. Anakinra offered rapid symptom relief but had frequent injection site reactions. Canakinumab provided sustained control with fewer local side effects but required monitoring for rare complications.<\/jats:p>\n                    <jats:sec>\n                      <jats:title>Key points<\/jats:title>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag015","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:40:15Z","timestamp":1771591215000},"page":"817-825","source":"Crossref","is-referenced-by-count":1,"title":["Real-world efficacy, safety, and drug retention of anakinra and canakinumab in paediatric colchicine-resistant familial Mediterranean fever: Insights from a single-centre cohort"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3014-5692","authenticated-orcid":false,"given":"\u015eeng\u00fcl","family":"\u00c7a\u011flayan","sequence":"first","affiliation":[{"name":"Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences , Istanbul ,","place":["Turkey"]},{"name":"Department of Pediatric Rheumatology, Antalya Training and Research Hospital, University of Health Sciences , Antalya ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taner","family":"Co\u015fkuner","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8197-6077","authenticated-orcid":false,"given":"Kadir","family":"Ulu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences , Istanbul ,","place":["Turkey"]},{"name":"Department of Pediatric Rheumatology, \u015eehit Prof. Dr \u0130lhan Varank Sancaktepe Training and Research Hospital, University of Health Sciences , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan Emre","family":"Yi\u011fit","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyma","family":"T\u00fcrkmen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclcan \u00d6zomay","family":"Baykal","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-6605","authenticated-orcid":false,"given":"Eray","family":"Tunce","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0131la Atamy\u0131ld\u0131z","family":"U\u00e7ar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5079-5644","authenticated-orcid":false,"given":"Bet\u00fcl","family":"S\u00f6zeri","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"2026083106413715500_ref1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/s0140-6736(97)09408-7","article-title":"Familial Mediterranean fever","volume":"351","author":"Ben-Chetrit","year":"1998","journal-title":"Lancet"},{"key":"2026083106413715500_ref2","doi-asserted-by":"publisher","first-page":"9584","DOI":"10.3390\/ijms24119584","article-title":"An update on familial Mediterranean fever","volume":"24","author":"Lancieri","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026083106413715500_ref3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng0997-25","article-title":"A candidate gene for familial Mediterranean fever","volume":"17","author":"French FMF Consortium","year":"1997","journal-title":"Nat Genet"},{"key":"2026083106413715500_ref4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3906\/sag-2008-11","article-title":"Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review","volume":"50","author":"Tufan","year":"2020","journal-title":"Turk J Med Sci"},{"key":"2026083106413715500_ref5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00296-015-3408-9","article-title":"Efficacy and safety of treatments in familial Mediterranean fever: a systematic review","volume":"36","author":"Demirkaya","year":"2016","journal-title":"Rheumatol Int"},{"key":"2026083106413715500_ref6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ard.2025.01.028","article-title":"EULAR\/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update","volume":"84","author":"Ozen","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026083106413715500_ref7","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1093\/rheumatology\/keaa863","article-title":"Defining colchicine resistance\/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach","volume":"60","author":"\u00d6zen","year":"2021","journal-title":"Rheumatology"},{"key":"2026083106413715500_ref8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semarthrit.2017.03.006","article-title":"Colchicine resistance and intolerance in familial Mediterranean fever: definition, causes, and alternative treatments","volume":"47","author":"Ozen","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2026083106413715500_ref9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3389\/fimmu.2020.00971","article-title":"The use of interleukine-1 inhibitors in familial Mediterranean fever patients: a narrative review","volume":"11","author":"Hentgen","year":"2020","journal-title":"Front Immunol"},{"key":"2026083106413715500_ref10","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/art.39995","article-title":"Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial","volume":"69","author":"Ben-Zvi","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2026083106413715500_ref11","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med"},{"key":"2026083106413715500_ref12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","article-title":"Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial","volume":"157","author":"Hashkes","year":"2012","journal-title":"Ann Intern Med"},{"key":"2026083106413715500_ref13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/rheumatology\/ken509","article-title":"A new set of criteria for the diagnosis of familial Mediterranean fever in childhood","volume":"48","author":"Yal\u00e7inkaya","year":"2009","journal-title":"Rheumatology"},{"key":"2026083106413715500_ref14","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1136\/annrheumdis-2019-215048","article-title":"Classification criteria for autoinflammatory recurrent fevers","volume":"78","author":"Gattorno","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026083106413715500_ref15","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1136\/annrheumdis-2013-203666","article-title":"Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes","volume":"73","author":"Piram","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026083106413715500_ref16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12969-021-00588-0","article-title":"Colchicine\u2014an effective treatment for children with a clinical diagnosis of autoinflammatory diseases without pathogenic gene variants","volume":"19","author":"Welzel","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026083106413715500_ref17","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2020-217419","article-title":"Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: Results from the randomised phase III CLUSTER trial","volume":"79","author":"Ozen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026083106413715500_ref18","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1093\/rheumatology\/keaa121","article-title":"Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry","volume":"59","author":"Sag","year":"2020","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026083106413715500_ref19","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1093\/rheumatology\/keaa596","article-title":"Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience","volume":"60","author":"Ugurlu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026083106413715500_ref20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acr.23446","article-title":"Nationwide experience with off-label use of interleukin-1 targeting treatment in familial Mediterranean fever patients","volume":"70","author":"Akar","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2026083106413715500_ref21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/14397595.2018.1559488","article-title":"Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients","volume":"30","author":"G\u00fclez","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2026083106413715500_ref22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.55563\/clinexprheumatol\/815tdt","article-title":"Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients","volume":"39","author":"Atas","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026083106413715500_ref23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.55563\/clinexprheumatol\/rrr9zd","article-title":"Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab","volume":"39","author":"Druyan","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026083106413715500_ref24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/rheumatology\/kead514","article-title":"Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis","volume":"63","author":"Kilic","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026083106413715500_ref25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.semarthrit.2010.11.003","article-title":"Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature","volume":"41","author":"Meinzer","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2026083106413715500_ref26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3109\/14397595.2014.987437","article-title":"Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients","volume":"25","author":"Ba\u015faran","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2026083106413715500_ref27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.46497\/ArchRheumatol.2022.8998","article-title":"Efficacy of anakinra treatment in pediatric rheumatic diseases: our single-center experience","volume":"37","author":"Demir","year":"2022","journal-title":"Arch Rheumatol"},{"key":"2026083106413715500_ref28","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1093\/rheumatology\/keaf221","article-title":"Predicting homozygous M694V genotype in paediatric FMF: multicentre analysis and scoring system proposal","volume":"64","author":"Tunce","year":"2025","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026083106413715500_ref29","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.55563\/clinexprheumatol\/pjs6eh","article-title":"Real-world safety and effectiveness of canakinumab in patients with cryopyrin-associated periodic fever syndrome: a long-term observational study in Japan","volume":"40","author":"Hosono","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026083106413715500_ref30","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","article-title":"Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials","volume":"77","author":"Ruperto","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026083106413715500_ref31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RHU.0000000000000873","article-title":"Effectiveness of canakinumab in colchicine- and anakinra-resistant or -intolerant adult familial Mediterranean fever patients: a single-center real-life study","volume":"26","author":"Babaoglu","year":"2020","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"2026083106413715500_ref32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10067-020-05267-1","article-title":"A case of cryopyrin-associated periodic fever syndrome during canakinumab administration complicated by inflammatory bowel disease","volume":"40","author":"Yamasaki","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026083106413715500_ref33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12969-017-0147-3","article-title":"Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis","volume":"15","author":"H\u00fcgle","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026083106413715500_ref34","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/art.42808","article-title":"Clinical characteristics of cryopyrin-associated periodic syndrome and long-term real-world efficacy and tolerability of canakinumab in Japan: results of a Nationwide survey","volume":"76","author":"Miyamoto","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026083106413715500_ref35","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/mog.0000000000000118","article-title":"Cytokines and mucosal immunity","volume":"30","author":"Bamias","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"2026083106413715500_ref36","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1136\/gutjnl-2012-303329","article-title":"Non-redundant properties of IL-1\u03b1 and IL-1\u03b2 during acute colon inflammation in mice","volume":"63","author":"Bersudsky","year":"2014","journal-title":"Gut"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag015\/67063099\/roag015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/817\/67063099\/roag015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/817\/67063099\/roag015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:41:43Z","timestamp":1788172903000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/5\/817\/8494268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,21]]},"published-print":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag015","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,2,21]]}}}